Neurocentre, University Hospital of the Saarland, Homburg/Saar.
World J Biol Psychiatry. 2010 Aug;11(5):709-18. doi: 10.3109/15622971003624197.
Treatment investigations with methylphenidate in adults with ADHD focus preferentially on the classical psychopathology: inattention, hyperactivity and impulsivity. ADHD-associated emotional symptoms, which are frequently present at least in ADHD subpopulations, were studied rarely. The vast majority of the placebo-controlled trials had observation periods between 4 and 8 weeks. To assess the medium- to long-term effects of extended release methylphenidate (MPH-ER) on emotional symptoms and other psychopathology frequently seen in ADHD patients, we conducted a large-scale, multicenter treatment study.
We performed a randomised, 24-week, double-blind, placebo-controlled study in adults with ADHD. The diagnosis was made on the basis of the DSM-IV criteria, which were confirmed by clinical history and a structured psychopathological interview and the use of rating instruments. 363 patients were randomized to MPH-ER or placebo at a ratio of 2:1. The duration of the titration period was 5 weeks followed by a maintainance phase of 19 weeks. The efficacy measures were the observer rated 10-item Emotional Dysregulation Scale (EDS) derived from the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and a self-report, six-item Emotional Lability Scale (ELS) extracted from the long version of the Conners Adult ADHD Self Report Scale (CAARS:S:L). In addition we used the SCL-90-R for the assessment of ADHD associated and comorbid psychopathology.
MPH-ER was statistically superior to placebo in reducing emotional symptoms as assessed by the EDS and the ELS. Obsessive-compulsive symptoms and those of problems with self-concept declined until the end of the observation period. The decline was more pronounced in MPH-ER treated individuals. The effects remained robust during the entire maintenance period until week 24. Symptoms of anxiety, depression, anger and hostility, phobia, paranoid ideations and psychoticism were not improved.
MPH-ER appears to be an efficacious treatment for emotional symptoms with ADHD. Also obsessive-compulsive symptoms and problems with self-concept were affected positively.
在注意力缺陷多动障碍(ADHD)成人患者中,使用哌甲酯治疗的研究主要集中在经典的精神病理学方面:注意力不集中、多动和冲动。然而,ADHD 相关的情绪症状在至少 ADHD 亚群中经常存在,却很少被研究。绝大多数安慰剂对照试验的观察期为 4 至 8 周。为了评估缓释哌甲酯(MPH-ER)对 ADHD 患者中经常出现的情绪症状和其他精神病理学的中至长期影响,我们进行了一项大规模、多中心的治疗研究。
我们对成人 ADHD 患者进行了一项随机、24 周、双盲、安慰剂对照研究。该诊断基于 DSM-IV 标准,通过临床病史和结构化精神病理学访谈以及使用评分工具进行确认。363 名患者按照 2:1 的比例随机分为 MPH-ER 组或安慰剂组。滴定期持续 5 周,随后维持期 19 周。疗效评估指标为观察评分的 10 项情绪失调量表(EDS),该量表源自 Wender-Reimherr 成人注意缺陷障碍量表(WRAADDS);以及自我报告的六项情绪不稳定性量表(ELS),该量表从 Conners 成人 ADHD 自评量表(CAARS:S:L)的长版本中提取。此外,我们还使用 SCL-90-R 评估 ADHD 相关和共病的精神病理学。
MPH-ER 在降低 EDS 和 ELS 评估的情绪症状方面,统计学上优于安慰剂。强迫症症状和自我概念问题的症状在观察期间持续下降。在 MPH-ER 治疗的个体中下降更为明显。这些效果在整个维持期直至第 24 周都保持稳健。焦虑、抑郁、愤怒和敌意、恐惧症、偏执观念和精神病性症状并未改善。
MPH-ER 似乎是治疗 ADHD 情绪症状的有效治疗方法。强迫症症状和自我概念问题也得到了积极的影响。